Clinical trials: Inflammatory Skin Disease
Sjogren's Disease
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).
- Trial name
- NCT02322528
- Testing
- Administration of Lotemax
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Acne, Post Inflammatory Hyperpigmentation
LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)
The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)
- Trial name
- NCT05327361
- Testing
- Liftactiv B3, Sunscreen
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris.
- Trial name
- NCT01038869
- Testing
- Azelaic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Research, PLLC
Breast Cancer
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function.
- Trial name
- NCT00464646
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 36 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NSABP Foundation Inc
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Herpes Simplex Virus, Neonatal Sepsis
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies. Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been adequately studied in full-term or premature neonates.
- Trial name
- NCT00942084
- Testing
- Acyclovir
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Phillip Brian Smith
Spondyloarthritis
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.
- Trial name
- Annexin 03 (NCT03232580)
- Testing
- rhAnnexin V-128
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Advanced Accelerator Applications
Systemic Lupus Erythematosus
A Phase II Study of M2951 in SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus…
- Trial name
- NCT02975336
- Testing
- M2951
- Where
- 157 sites in United States, Argentina and 17 more
- Volunteers
- 469 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Breast Cancer
Phase II Neoadjuvant in Inflammatory Breast Cancer
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to…
- Trial name
- NCT00756470
- Testing
- Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various…
- Conditions
- Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia
- Trial name
- STOP-NT (NCT01734694)
- Testing
- Vancomycin, Ceftaroline, Daptomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Henry Ford Health System
Gastric Ulcer, Duodenal Ulcer
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00542789
- Testing
- Esomeprazole
- Where
- 39 sites in Japan
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Osteoarthritis, Rheumatoid Arthritis
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome
- Trial name
- NCT00984815
- Testing
- HZT-501
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Edema, Erythema
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative
- Trial name
- NCT02411656
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Rosacea
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
- Trial name
- NCT02800148
- Testing
- Azelaic acid foam
- Where
- United States
- Volunteers
- 667 people
- Sponsor
- Padagis LLC
Psoriatic Arthritis
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.
- Trial name
- PALACE 3 (NCT01212770)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 505 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Metastatic Breast Cancer, Breast Cancer
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer.
- Trial name
- NCT05243641
- Testing
- Neratinib, Capmatinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center